Daily Markup

Daily Markup #789: Prenetics joins forces with renowned scientist Dennis Lo to combat cancer with affordable early detection test

July 19, 2023 · 2 min read
Credit: Prenetics

Dan and Denn bring you better healthcare

  • The Big C is coming face-to-face with a formidable duo! 500-backed biotech company Prenetics and globally-renowned scientist Dennis Lo established Insighta, a US$200M joint venture that will offer a new, revolutionary genetic test for detecting various types of cancers. This marks one of the largest private life sciences deals in Hong Kong, and one of the largest in the region.
  • Prenetics Co-founder & CEO Danny Yeung, who will also serve as CEO of Insighta, shared, “Our plan is to leverage our existing capabilities in genetic testing, data analysis, and bioinformatics to validate, optimize and scale this technology. It’s about merging our resources with this incredible scientific breakthrough to create a solution that’s scalable and accessible.”
  • “The potential of our Presight test is immense, potentially influencing the health of 1 billion individuals in Asia,” he added. Insighta will focus on launching in Mainland China, Hong Kong, and other parts of Asia, while keeping a keen eye out for global alliances to scale their mission of combating cancer.
  • The best part The multi-cancer test will be priced at less than US$200 each. “Insighta exemplifies our commitment to advancing science for the betterment of global health. Our objective is to transform early cancer detection from a luxury to a universally accessible necessity,” Danny said.
  • Read the full story on Tatler Asia.
Daily
Tags:
0
Share
• • • KEEP READING

Daily Markup

  • Daily Markup is brought to you by 500 Global, Southeast Asia

  • All content herein is intended solely for general informational or educational purposes only. 500 Startups Management Company, L.L.C. and its affiliates (collectively “500 Global”) makes no representation as to the accuracy or information in this post and while reasonable steps have been taken to ensure that the information herein is accurate and up-to-date, no liability can be accepted for any error or omissions. All third party links in this post have not been independently verified by 500 Global and the inclusion of such links should not be interpreted as an endorsement or confirmation of the content within. Information about portfolio companies’ markets, competitors, performance, and fundraising has been provided by those companies’ founders and has not been independently verified. Under no circumstances should any content in this post be construed as investment, legal, tax or accounting advice by 500 Global, or an offer to provide any investment advisory service with regard to securities by 500 Global. No content or information in this post should be construed as an offer to sell or solicitation of interest to purchase any securities advised by 500 Global. Prospective investors considering an investment into any 500 Global fund should not consider or construe this content as fund marketing material. The views expressed herein are as at the date of this post and are subject to change without notice. One or more 500 Global fund may have a financial interest in one or more of the companies discussed

    All users of this website should note these important Terms of Use governing the use of this website.

  • Copyright © 2024 500 Global | All Rights Reserved

  • Privacy Policy
    Terms of Use
    Code of Conduct